Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.54 |
| ▸ | AXL | P30530 | 13/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | ABL2 | P42684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18044629 | 0.90 | MET (0.43) | METAXLFLT3EGFRSRC | |
| SCHEMBL18044553 | 0.86 | FLT3 (0.48) | METAXLFLT3MERTKEGFR | |
| SCHEMBL18044612 | 0.85 | SRC (0.51) | METFLT3MERTKEGFRSRC | |
| SCHEMBL18044610 | 0.85 | SRC (0.51) | METFLT3MERTKEGFRSRC | |
| SCHEMBL18044676 | 0.85 | AXL (0.47) | METAXLFLT3MERTK | |
| SCHEMBL18044618 | 0.83 | AXL (0.58) | METAXLFLT3MERTK | |
| SCHEMBL22418549 | 0.83 | MET (0.56) | METAXLFLT3MERTKEGFR | |
| SCHEMBL18044588 | 0.82 | AXL (0.59) | METAXLFLT3MERTKEGFR | |
| SCHEMBL18044562 | 0.81 | MET (0.57) | METAXLFLT3 | |
| SCHEMBL16709460 | 0.81 | MET (0.57) | METAXLFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3067356-B1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9586967-B2 | Pyrrolo pyrimidine derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3067356-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | AXL, FLT3, TYRO3 | MET 398/4885AXL 1/4885FLT3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.